Latest Period
Q2 2026
Security Snapshot
Mineralys Therapeutics, Inc. - COMMON STOCK (MLYS) Institutional Ownership
CUSIP: 603170101
13F Institutional Holders and Ownership History from Q1 2023 to Q2 2026
Institutions Reporting
223
Shares (Excl. Options)
99,595,011
Price
$26.98
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- MLYS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 99,595,011
- Total 13F value
- $2,687,207,911
- Portfolio coverage rank
- 0.01%
- Share change
- +9,333,306
- Value change
- +$251,180,033
- Number of holders
- 223
- Shares outstanding
- 87,484,107
- SEC-reported price per share
- $26.71
- Insider filing price
- $26.71
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- MLYS - Mineralys Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 603170101.
- 223 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 213 to 223 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,455,035,905 to $2,687,207,911.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 223 institutions filings for Q2 2026.
Security key
603170101
Latest holder period
Q2 2026
13F holders
223
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
MLYS full holder history
Mineralys Therapeutics, Inc. SEC filings
Mineralys Therapeutics, Inc. company facts
Mineralys Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 603170101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
MLYS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Catalys Pacific Fund, LP | 10% | -24% | $267,051,367 | -$32,576,328 | 8,002,738 | -11% | Catalys Pacific Fund, LP | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $104,939,988 | +$20,308,933 | 7,796,433 | +24% | RA Capital Management, L.P. | 04 Sep 2025 |
| Samsara BioCapital, L.P. | 8.2% | -10% | $85,419,771 | +$8,209,106 | 6,346,194 | +11% | Srinivas Akkaraju | 04 Sep 2025 |
| FMR LLC | 5.1% | -20% | $123,544,181 | -$15,390,656 | 4,461,689 | -11% | FMR LLC | 30 Jun 2026 |
| BlackRock, Inc. | 5.2% | $149,286,258 | 4,113,657 | BlackRock, Inc. | 31 Dec 2025 | |||
| Andera Partners | 4.2% | $39,747,075 | 2,765,976 | Andera Partners | 30 Jun 2025 | |||
| ADAMS STREET PARTNERS LLC | 2.3% | $15,320,183 | 1,129,807 | Adams Street Partners, LLC | 31 Dec 2024 |
As of 30 Jun 2026, 223 institutional investors reported holding 99,595,011 shares of Mineralys Therapeutics, Inc. - COMMON STOCK (MLYS). This represents 114% of the company’s total 87,484,107 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
81%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Catalys Pacific, LLC | 9% | 7,903,838 | 0% | 93% | $213,245,549 |
| RA CAPITAL MANAGEMENT, L.P. | 8.8% | 7,692,750 | 0% | 1.8% | $207,550,395 |
| BlackRock, Inc. | 6.7% | 5,887,038 | +31% | 0% | $158,832,288 |
| SAMSARA BIOCAPITAL, LLC | 6.7% | 5,871,018 | 0% | 13% | $158,400,066 |
| FMR LLC | 5.2% | 4,511,689 | -7.2% | 0.01% | $121,725,382 |
| STATE STREET CORP | 4.7% | 4,141,636 | +41% | 0% | $111,741,339 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4.5% | 3,958,000 | 1.1% | $106,786,840 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 2,756,770 | +12% | 0% | $74,377,655 |
| Laurion Capital Management LP | 2.9% | 2,506,152 | +12% | 4.9% | $67,615,981 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.6% | 2,262,476 | +68% | 0.01% | $61,042,000 |
| ORBIMED ADVISORS LLC | 2.4% | 2,110,300 | +2.8% | 1.1% | $56,935,894 |
| Capital World Investors | 2.3% | 1,997,607 | +402% | 0.01% | $53,895,437 |
| ARMISTICE CAPITAL, LLC | 2% | 1,736,000 | +48% | 1.3% | $46,837,280 |
| Troluce Capital Advisors LLC | 2% | 1,728,753 | +164% | 17% | $46,641,756 |
| FRANKLIN RESOURCES INC | 1.9% | 1,635,520 | -8.4% | 0.01% | $44,126,329 |
| ANDERA PARTNERS | 1.8% | 1,591,917 | 0% | 21% | $42,949,921 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,584,326 | +22% | 0% | $42,753,193 |
| SR One Capital Management, LP | 1.8% | 1,563,966 | 0% | 4.1% | $42,195,803 |
| BANK OF AMERICA CORP /DE/ | 1.7% | 1,505,547 | +37% | 0% | $40,619,658 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.7% | 1,469,971 | +9.7% | 5.7% | $39,659,818 |
| GOLDMAN SACHS GROUP INC | 1.7% | 1,458,676 | +86% | 0% | $39,355,079 |
| Pictet Asset Management Holding SA | 1.6% | 1,430,649 | +38% | 0.04% | $38,598,910 |
| Polar Capital Holdings Plc | 1.6% | 1,420,854 | -5.3% | 0.11% | $38,334,641 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 1,221,758 | +133% | 0.02% | $32,963,031 |
| Ghisallo Capital Management LLC | 1.3% | 1,125,000 | 0.6% | $30,352,500 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
14
Latest
Q2 2026
Rows shown
1-14 of 14
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 99,595,011 | $2,687,207,911 | +$251,180,033 | $26.98 | 223 |
| 2026 Q1 | 90,325,196 | $2,455,035,905 | -$6,333,390 | $27.09 | 213 |
| 2025 Q4 | 88,390,661 | $3,207,524,350 | +$270,032,812 | $36.29 | 223 |
| 2025 Q3 | 79,306,949 | $3,007,317,130 | +$505,416,563 | $37.92 | 191 |
| 2025 Q2 | 65,687,280 | $888,767,559 | +$52,640,107 | $13.53 | 164 |
| 2025 Q1 | 61,178,854 | $971,385,613 | +$245,430,113 | $15.88 | 148 |
| 2024 Q4 | 46,486,259 | $572,248,542 | +$24,847,746 | $12.31 | 108 |
| 2024 Q3 | 44,382,325 | $540,052,185 | +$2,379,010 | $12.11 | 105 |
| 2024 Q2 | 44,151,028 | $516,569,023 | +$24,151,320 | $11.70 | 93 |
| 2024 Q1 | 41,871,642 | $540,562,541 | +$93,970,804 | $12.91 | 91 |
| 2023 Q4 | 34,713,391 | $298,534,855 | -$5,432,193 | $8.60 | 87 |
| 2023 Q3 | 26,512,068 | $252,135,025 | -$9,247,223 | $9.51 | 77 |
| 2023 Q2 | 25,186,898 | $429,224,695 | +$10,759,767 | $17.05 | 68 |
| 2023 Q1 | 24,614,198 | $385,431,208 | +$385,431,208 | $15.66 | 66 |